Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Measurable Residual Disease Monitoring in AML With FLT3-ITD Treated With Intensive Chemotherapy Plus Midostaurin.
Rücker FG, Bullinger L, Cocciardi S, Skambraks S, Luck TJ, Weber D, Krzykalla J, Pozek E, Schneider IJ, Corbacioglu A, Gaidzik VI, Meid A Dr, Aicher S, Stegelmann F, Schrade A, Theis F, Fiedler W, Salih HR, Wulf GG, Salwender HJ, Schroeder T, Götze KS, Kühn MWM, Lübbert M, Schlenk RF, Benner A, Thol FR, Heuser M, Ganser A, Döhner H, Döhner K. Rücker FG, et al. Blood Adv. 2024 Sep 30:bloodadvances.2024013758. doi: 10.1182/bloodadvances.2024013758. Online ahead of print. Blood Adv. 2024. PMID: 39348668
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.
Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K. Rücker FG, et al. Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425. Blood. 2019. PMID: 31554635 Free PMC article.
Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication.
Jahn N, Terzer T, Sträng E, Dolnik A, Cocciardi S, Panina E, Corbacioglu A, Herzig J, Weber D, Schrade A, Götze K, Schröder T, Lübbert M, Wellnitz D, Koller E, Schlenk RF, Gaidzik VI, Paschka P, Rücker FG, Heuser M, Thol F, Ganser A, Benner A, Döhner H, Bullinger L, Döhner K. Jahn N, et al. Among authors: rucker fg. Blood Adv. 2020 Dec 22;4(24):6342-6352. doi: 10.1182/bloodadvances.2020002673. Blood Adv. 2020. PMID: 33351131 Free PMC article.
Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial.
Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik VI, Paschka P, Krönke J, Theis F, Rücker FG, Teleanu MV, Panina E, Jahn N, Herzig J, Kubanek L, Schrade A, Göhring G, Fiedler W, Kindler T, Schroeder T, Mayer KT, Lübbert M, Wattad M, Götze KS, Horst HA, Koller E, Wulf G, Schleicher J, Bentz M, Krauter J, Bullinger L, Krzykalla J, Benner A, Schlenk RF, Thol F, Heuser M, Ganser A, Döhner H, Döhner K. Kapp-Schwoerer S, et al. Among authors: rucker fg. Blood. 2020 Dec 24;136(26):3041-3050. doi: 10.1182/blood.2020005998. Blood. 2020. PMID: 33367545 Free article. Clinical Trial.
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock LK, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, Panina E, Blätte TJ, Herzig J, Skambraks S, Rücker FG, Gaidzik VI, Paschka P, Fiedler W, Salih HR, Wulf G, Schroeder T, Lübbert M, Schlenk RF, Thol F, Heuser M, Larson RA, Ganser A, Stunnenberg HG, Minucci S, Stone RM, Bloomfield CD, Döhner H, Döhner K, Bullinger L. Schmalbrock LK, et al. Among authors: rucker fg. Blood. 2021 Jun 3;137(22):3093-3104. doi: 10.1182/blood.2020007626. Blood. 2021. PMID: 33598693 Free PMC article. Clinical Trial.
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, Paschka P, Held G, von Lilienfeld-Toal M, Lübbert M, Fröhling S, Zenz T, Krauter J, Schlegelberger B, Ganser A, Lichter P, Döhner K, Döhner H. Rücker FG, et al. Blood. 2012 Mar 1;119(9):2114-21. doi: 10.1182/blood-2011-08-375758. Epub 2011 Dec 20. Blood. 2012. PMID: 22186996 Free article.
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.
Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rücker FG, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K. Krönke J, et al. Among authors: rucker fg. Blood. 2013 Jul 4;122(1):100-8. doi: 10.1182/blood-2013-01-479188. Epub 2013 May 23. Blood. 2013. PMID: 23704090 Free article.
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.
Rücker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Döhner H, Thiede C, Döhner K. Rücker FG, et al. Leukemia. 2022 Jan;36(1):90-99. doi: 10.1038/s41375-021-01323-0. Epub 2021 Jul 28. Leukemia. 2022. PMID: 34316017 Free PMC article. Clinical Trial.
42 results